ANI Pharmaceuticals, Inc. (ANIP)
- Previous Close
58.30 - Open
58.58 - Bid 58.75 x 100
- Ask 58.91 x 100
- Day's Range
58.00 - 59.08 - 52 Week Range
48.20 - 70.81 - Volume
184,636 - Avg. Volume
345,080 - Market Cap (intraday)
1.236B - Beta (5Y Monthly) 0.71
- PE Ratio (TTM)
49.39 - EPS (TTM)
1.19 - Earnings Date Nov 6, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
82.40
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
www.anipharmaceuticals.com642
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: ANIP
View MorePerformance Overview: ANIP
Trailing total returns as of 9/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ANIP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ANIP
View MoreValuation Measures
Market Cap
1.24B
Enterprise Value
1.30B
Trailing P/E
49.39
Forward P/E
9.63
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.11
Price/Book (mrq)
2.71
Enterprise Value/Revenue
2.41
Enterprise Value/EBITDA
11.13
Financial Highlights
Profitability and Income Statement
Profit Margin
5.01%
Return on Assets (ttm)
3.38%
Return on Equity (ttm)
5.90%
Revenue (ttm)
538.95M
Net Income Avi to Common (ttm)
22.93M
Diluted EPS (ttm)
1.19
Balance Sheet and Cash Flow
Total Cash (mrq)
247.05M
Total Debt/Equity (mrq)
60.32%
Levered Free Cash Flow (ttm)
82.53M